Bioidentical vs synthetic hormones

What it is

Bioidentical hormones are compounds whose chemical and molecular structure is identical to the hormones produced naturally by the human body — most commonly estradiol, progesterone, and testosterone — and they are already present in the majority of Health Canada–approved hormone therapy (HT) products prescribed across Canada today. The term "bioidentical hormone therapy" (BHT) is sometimes used interchangeably with "natural hormone therapy," though the two are not synonymous: "natural" refers to the plant-derived source material (typically soy or wild yam), while "bioidentical" refers strictly to molecular identity with endogenous hormones. By contrast, synthetic hormones — such as medroxyprogesterone acetate (MPA) or conjugated equine estrogens (CEE) — have molecular structures that differ from those the body makes, which affects how they bind to receptors and how they are metabolized.

A key point that surprises many Canadian patients: Health Canada–approved products like estradiol (Estrace, Estrogel, Climara) and micronized progesterone (Prometrium) are bioidentical by definition. The debate is not really "bioidentical vs. approved HT" — it is "regulated bioidentical HT vs. custom-compounded bioidentical preparations," a distinction with real safety implications.

Causes and mechanism

The distinction between bioidentical and synthetic hormones matters at the receptor level. Bioidentical estradiol binds estrogen receptors (ERα and ERβ) with the same affinity as endogenous estradiol. Synthetic progestins like MPA, used in older HT regimens, bind not only progesterone receptors but also androgen and glucocorticoid receptors, producing off-target effects that micronized progesterone does not. A 2007 comprehensive review in Postgraduate Medicine noted these receptor-binding differences may translate into clinically meaningful distinctions — particularly regarding breast tissue and cardiovascular effects — though the authors cautioned that large-scale head-to-head RCT data remain limited.

The "compounded bioidentical" category introduces a separate variable: custom-mixed preparations from compounding pharmacies are not subject to the same manufacturing standards as Health Canada–approved drugs. Dose consistency, sterility, and shelf stability can vary batch to batch.

Symptoms and diagnosis

This entry covers a treatment category rather than a disease, so "diagnosis" applies to the underlying conditions for which HT is prescribed — most commonly:

Condition	Typical hormone used	Regulatory status in Canada
Menopausal vasomotor symptoms	Estradiol ± progesterone	Health Canada–approved options available
Genitourinary syndrome of menopause	Low-dose vaginal estradiol	Health Canada–approved
Hypogonadism (male or female)	Testosterone	Approved for men; off-label for women
Surgical menopause	Estradiol ± progesterone	Health Canada–approved
Compounded "custom" HT	Variable hormones + doses	Not Health Canada–approved

Clinicians assess hormone levels through serum blood tests (available at LifeLabs and Dynacare across Canada). Saliva hormone testing, often marketed alongside compounded BHT, does not reliably reflect serum levels and is not recommended by the Society of Obstetricians and Gynaecologists of Canada (SOGC) for guiding HT dosing.

Treatment options

For most patients, the practical choice is between:

1. Regulated bioidentical HT — Health Canada–approved estradiol and micronized progesterone (Prometrium). These have established safety and efficacy data, standardized dosing, and provincial drug benefit coverage in many provinces (e.g., Ontario Drug Benefit, BC PharmaCare).

2. Synthetic HT — Products containing MPA or CEE (e.g., Premarin, Provera, Prempro). These have the largest long-term trial evidence base, including the Women's Health Initiative (WHI, 2002), though the WHI used CEE + MPA, not bioidentical hormones, and its findings are not directly transferable to bioidentical regimens.

3. Compounded bioidentical HT — Custom preparations from compounding pharmacies. These may be appropriate in rare cases where a patient cannot tolerate any approved formulation (e.g., allergy to an excipient), but they carry no Health Canada approval, no standardized quality assurance, and no long-term safety data. The SOGC and The Menopause Society both advise against routine use of compounded BHT when approved alternatives exist.

Testosterone therapy for women (for hypoactive sexual desire disorder) remains off-label in Canada; no female-specific testosterone product is currently Health Canada–approved, so clinicians typically use male-formulation products at lower doses or compounded preparations — a genuine gap in the regulated market.

When to see a clinician in Canada

Any patient considering hormone therapy — bioidentical or otherwise — should have a full medical history review before starting, including personal and family history of breast cancer, cardiovascular disease, and thromboembolic events. In Canada, HT is available through family physicians, gynecologists, and menopause specialists. Virtual prescribing platforms (Felix, Cleo, Maple, Phoenix, and others) can initiate or renew HT prescriptions for appropriate candidates. Patients interested in compounded preparations should ask their prescriber specifically why an approved product would not meet their needs, and request documentation of the compounding pharmacy's quality standards.

Provincial drug plans vary: Prometrium and estradiol patches are listed on several provincial formularies, but coverage criteria differ. Patients should check their provincial benefit list or ask a pharmacist before assuming coverage.

Limitations and open questions

Research is still emerging on several fronts. Head-to-head randomized controlled trials directly comparing bioidentical and synthetic progestins on hard endpoints (breast cancer incidence, cardiovascular events, venous thromboembolism) are limited; most evidence comes from observational studies, which carry confounding risks. The large French E3N cohort suggested a lower breast cancer risk with estradiol plus micronized progesterone compared to estradiol plus synthetic progestins, but this has not been confirmed in a large RCT.

Health Canada has not issued specific guidance distinguishing bioidentical from synthetic HT in terms of risk classification — both categories are regulated under the same drug approval framework when sold as approved products. The regulatory gap for compounded preparations is acknowledged but not fully resolved. Long-term safety data for testosterone therapy in women are also sparse, and no Canadian clinical guideline has yet established a standard dosing protocol for this indication. Patients and clinicians should treat marketing claims about compounded BHT being "safer" or "more natural" with skepticism until stronger evidence exists.